secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056994
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio Q1 revenue $3.4M down 46% YoY; net loss $8.6M improves from $11.1M
------------------------------------------------------------------------------

- Revenue $3.4M vs $6.3M YoY; product revenue fell $1.7M and collaboration revenue $1.0M.
- Net loss $8.6M ($5.52 EPS) vs $11.1M ($6.75 EPS) YoY; operating expenses cut 31% to $10.0M.
- Cash, equivalents and investments $15.7M at March 31, 2024; long-term notes payable $5.2M.
- Strategic focus on Gibson SOLA and BioXp mRNA; 40% of new instrument buyers cite mRNA workflow.
- Pfizer collaboration progressing; no forward-looking guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/0000950170-24-056994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/tbio-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer